Such studies will be essential to fully delineate the therapeutic potential of statin-mediated PAR-2 modulation in CRC and its impact on tumour progression, angiogenesis, and the inflammatory tumour microenvironment. The gene discussed is F2RL1; the disease is neoplasm.